Quince Therapeutics Inc

Quince Therapeutics Faces Sharp Downgrade After Phase‑3 Failure

Quince Therapeutics drops its Phase‑3 eDSP study, prompting analyst downgrades and a sharp stock decline—will its precision delivery platform rebound?

30/01/2026, 20:40

3 minutes to read

Quince Therapeutics Inc: Navigating Financial and Operational Challenges Amidst Innovative Bone Disease Therapies

Quince Therapeutics Inc faces significant financial and operational challenges that threaten its future prospects, despite its innovative approach to treating bone diseases.

25/06/2025, 22:18

3 minutes to read

Quince Therapeutics Innovates in Precision Bone Disease Treatments with Targeted Delivery Systems

Quince Therapeutics is a biopharmaceutical company pioneering precision therapeutics for bone diseases, aiming to revolutionize treatment by delivering targeted therapies directly to disease sites.

13/05/2025, 14:42

2 minutes to read

Quince Therapeutics: Pioneering Precision Therapeutics in Bone Disease Treatment

Quince Therapeutics, Inc. is a biopharmaceutical company innovating precision therapeutics for bone diseases, with a dynamic stock performance reflecting the industry’s volatility.

05/05/2025, 13:40

3 minutes to read